CTOR — Citius Oncology Share News
0.000.00%
Last trade - 00:00Citius Oncology Inc expected to post a loss of 5 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-AnaptysBio, Tesla, Intel
U.S. STOCKS ON THE MOVE-Dycom Industries, Robinhood, Brown-Forman
Citius rises as lymphoma drug shows benefit in patients before CAR-T therapy
Brief: Citius Oncology Announces Preliminary Topline Phase 1 Data From Study Of Lymphir™ (E7777) Dosing Prior To Commercial Car‑T Therapy In High‑Risk Diffuse Large B‑Cell Lymphoma
Brief: Citius Oncology Expands International Distribution Of Lymphir™ To European Union Through Exclusive Agreement With Uniphar
Brief: Citius Oncology Announces $18 Million Concurrent Registered Direct Offering And Private Placement Priced At-The-Market Under Nasdaq Rules
Brief: Citius Oncology Expands Lymphir Distribution To Turkey And Middle East Countries
Brief: Citius Oncology Announces U.S. Commercial Launch Of Lymphir For Cutaneous T-Cell Lymphoma
Brief: Citius Oncology Signs U.S. Distribution Agreement With Mckesson To Support Lymphir Commercial Launch
Brief: Citius Oncology Signs Exclusive Commercialization Agreement With EVERSANA To Support Planned Q4 2025 Launch Of LYMPHIR
Brief: Citius Oncology Enters Exclusive Distribution Agreement With Integris Pharma S.A.
Brief: Citius Oncology Announces Closing Of $9 Million Registered Direct Offering And Concurrent Private Placement
Brief: Citius Oncology Prices $9M Direct Offering & Private Placement
Brief: Citius Oncology Announces Closing Of $9.0 Million Public Offering
Brief: Citius Oncology Enters Into Distribution Services Agreement With Cardinal Health
Brief: Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results And Provides Business Update
Brief: Citius Oncology Inc - Receives Nasdaq Notice For Bid Price Non-Compliance - SEC Filing
Brief: Citius Oncology Reports Fiscal Full Year 2024 Financial Results And Provides Business Update